162 related articles for article (PubMed ID: 22988922)
1. Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease.
Han NY; Kim EH; Choi J; Lee H; Hahm KB
J Dig Dis; 2012 Oct; 13(10):497-503. PubMed ID: 22988922
[TBL] [Abstract][Full Text] [Related]
2. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease.
Han NY; Choi W; Park JM; Kim EH; Lee H; Hahm KB
J Dig Dis; 2013 Apr; 14(4):166-74. PubMed ID: 23320753
[TBL] [Abstract][Full Text] [Related]
3. Proteomics technologies for the global identification and quantification of proteins.
Brewis IA; Brennan P
Adv Protein Chem Struct Biol; 2010; 80():1-44. PubMed ID: 21109216
[TBL] [Abstract][Full Text] [Related]
4. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients.
Nanni P; Levander F; Roda G; Caponi A; James P; Roda A
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3127-36. PubMed ID: 19683480
[TBL] [Abstract][Full Text] [Related]
5. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review.
Gisbert JP; Chaparro M
J Crohns Colitis; 2019 Mar; 13(3):374-384. PubMed ID: 30307487
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.
Bennike T; Birkelund S; Stensballe A; Andersen V
World J Gastroenterol; 2014 Mar; 20(12):3231-44. PubMed ID: 24696607
[TBL] [Abstract][Full Text] [Related]
8. The proteomic advantage: label-free quantification of proteins expressed in bovine milk during experimentally induced coliform mastitis.
Boehmer JL; DeGrasse JA; McFarland MA; Tall EA; Shefcheck KJ; Ward JL; Bannerman DD
Vet Immunol Immunopathol; 2010 Dec; 138(4):252-66. PubMed ID: 21067814
[TBL] [Abstract][Full Text] [Related]
9. Proteomic insights on the metabolism in inflammatory bowel disease.
Pisani LF; Moriggi M; Gelfi C; Vecchi M; Pastorelli L
World J Gastroenterol; 2020 Feb; 26(7):696-705. PubMed ID: 32116417
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomics for identification of cancer biomarkers.
Chaerkady R; Pandey A
Proteomics Clin Appl; 2007 Sep; 1(9):1080-9. PubMed ID: 21136759
[TBL] [Abstract][Full Text] [Related]
11. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
Ekegren T; Hanrieder J; Bergquist J
J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
[TBL] [Abstract][Full Text] [Related]
12. Protein patterns in serum and peritoneal fluid in Crohn's disease and ulcerative colitis.
Haglund U; Hultén L
Acta Chir Scand; 1976; 142(2):160-4. PubMed ID: 936940
[TBL] [Abstract][Full Text] [Related]
13. Identification of biomarkers indicating cellular changes after treatment of neuronal cells with the C3 exoenzyme from Clostridium botulinum using the iTRAQ protocol and LC-MS/MS analysis.
Muetzelburg MV; Hofmann F; Just I; Pich A
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1344-51. PubMed ID: 19109081
[TBL] [Abstract][Full Text] [Related]
14. Quantitative protein profiling by mass spectrometry using label-free proteomics.
Haqqani AS; Kelly JF; Stanimirovic DB
Methods Mol Biol; 2008; 439():241-56. PubMed ID: 18370108
[TBL] [Abstract][Full Text] [Related]
15. Global and targeted quantitative proteomics for biomarker discovery.
Veenstra TD
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):3-11. PubMed ID: 17023222
[TBL] [Abstract][Full Text] [Related]
16. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
Nanni P; Parisi D; Roda G; Casale M; Belluzzi A; Roda E; Mayer L; Roda A
Rapid Commun Mass Spectrom; 2007; 21(24):4142-8. PubMed ID: 18022963
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Identification of the Plasma Proteomic Signature of Inflammatory Bowel Disease.
Di Narzo AF; Brodmerkel C; Telesco SE; Argmann C; Peters LA; Li K; Kidd B; Dudley J; Cho J; Schadt EE; Kasarskis A; Dobrin R; Hao K
J Crohns Colitis; 2019 Mar; 13(4):462-471. PubMed ID: 30445421
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
19. Diagnostics of inflammatory bowel disease.
Nikolaus S; Schreiber S
Gastroenterology; 2007 Nov; 133(5):1670-89. PubMed ID: 17983810
[TBL] [Abstract][Full Text] [Related]
20. Release of tissue-specific proteins into coronary perfusate as a model for biomarker discovery in myocardial ischemia/reperfusion injury.
Cordwell SJ; Edwards AV; Liddy KA; Moshkanbaryans L; Solis N; Parker BL; Yong AS; Wong C; Kritharides L; Hambly BD; White MY
J Proteome Res; 2012 Apr; 11(4):2114-26. PubMed ID: 22250753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
